BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals submitted its Q1 FY26 unaudited results, reviewed by statutory auditors P. Murali & Co. with a clean review report (no qualifications). On a standalone basis, revenue from operations fell to Rs. 1,670.82 lakhs from Rs. 1,902.58 lakhs in Q1 FY25, a roughly 12% YoY decline, while net profit collapsed to just Rs. 19.49 lakhs from Rs. 137.63 lakhs. On a consolidated basis, revenue grew about 7.8% YoY to Rs. 7,074.21 lakhs, but net profit plunged sharply to Rs. 29.01 lakhs from Rs. 648.04 lakhs as administrative expenses roughly doubled YoY. The Board also shared an update on the company's first pharmaceutical formulation plant at Jadcherla, Hyderabad, where installation/operational/performance qualifications are complete and stability batch production is expected to start from early September 2025. Additionally, wholly-owned subsidiary Balaxi Global DMCC acquired 100% of Balaxi Healthcare Nicaragua during the quarter, expanding the Latin American footprint.
Despite modest consolidated revenue growth, the sharp drop in profitability on both standalone and consolidated bases signals significant near-term margin pressure, likely tied to higher admin costs and pre-operational expenses for the new Jadcherla plant. For shareholders, this is a weak quarter on earnings, though the clean auditor review, plant commissioning progress, and Nicaragua acquisition point to growth investments that could support margins once commercial production begins.